Aclaris Therapeutics (ACRS) to Release Earnings on Thursday

Key Points

• Aclaris Therapeutics will report Q1 2026 results before the market opens on Thursday, May 14, 2026 (earnings call 12:30 PM ET); analysts expect EPS of ($0.16) and revenue of about $1.237 million.
• The company recently missed its prior-quarter estimates (reported ($0.16) EPS vs. ($0.15) consensus and $1.30M revenue vs. $2.07M expected) and shows a very large negative net margin (829.58%); analysts forecast roughly ($1) EPS for the current and next fiscal year.
• A major shareholder, Braden Michael Leonard, sold 300,000 shares at about $4.53 on April 23; the stock trades near $4.78 with a market cap of ~$667.6M, and analysts hold a consensus "Buy" rating with a $11 price target.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Aclaris Therapeutics to post earnings of ($0.16) per share and revenue of $1.2370 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS opened at $4.78 on Thursday. The stock has a 50 day moving average price of $3.80 and a 200 day moving average price of $3.24. Aclaris Therapeutics has a 52 week low of $1.16 and a 52 week high of $4.89. The stock has a market capitalization of $667.57 million, a PE ratio of -9.02 and a beta of 0.76.

Insider Buying and Selling at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the firm's stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total value of $1,359,000.00. Following the sale, the insider owned 13,950,000 shares of the company's stock, valued at approximately $63,193,500. This trade represents a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently modified their holdings of ACRS. Quadrature Capital Ltd boosted its stake in shares of Aclaris Therapeutics by 82.8% in the 4th quarter. Quadrature Capital Ltd now owns 57,670 shares of the biotechnology company's stock worth $174,000 after buying an additional 26,117 shares during the last quarter. Man Group plc purchased a new position in Aclaris Therapeutics in the fourth quarter valued at approximately $128,000. Intech Investment Management LLC lifted its stake in Aclaris Therapeutics by 19.8% in the fourth quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company's stock valued at $140,000 after purchasing an additional 7,702 shares during the last quarter. Algert Global LLC lifted its stake in Aclaris Therapeutics by 64.7% in the third quarter. Algert Global LLC now owns 65,630 shares of the biotechnology company's stock valued at $125,000 after purchasing an additional 25,780 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Aclaris Therapeutics by 7.4% in the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 6,271 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Analyst Upgrades and Downgrades

ACRS has been the topic of several research analyst reports. Guggenheim initiated coverage on Aclaris Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $12.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Aclaris Therapeutics in a research note on Friday, March 27th. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a research note on Thursday, March 19th. Wedbush upped their price objective on Aclaris Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Wednesday, April 29th. Finally, UBS Group set a $10.00 price objective on Aclaris Therapeutics in a research note on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $11.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.